V501 + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Anogenital Human Papilloma Virus Infection
Conditions
Anogenital Human Papilloma Virus Infection, Condyloma Acuminata
Trial Timeline
Jun 27, 2013 → Aug 30, 2017
NCT ID
NCT01862874About V501 + Placebo
V501 + Placebo is a phase 3 stage product being developed by Merck for Anogenital Human Papilloma Virus Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01862874. Target conditions include Anogenital Human Papilloma Virus Infection, Condyloma Acuminata.
What happened to similar drugs?
0 of 1 similar drugs in Anogenital Human Papilloma Virus Infection were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01862874 | Phase 3 | Completed |
Competing Products
3 competing products in Anogenital Human Papilloma Virus Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Topical NO + Placebo | Kyowa Kirin | Phase 2 | 35 |
| V501 | Merck | Phase 3 | 40 |
| AP611074 + Placebo | Vaxart | Phase 1/2 | 22 |